CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,035 | $46.17 | $94K | 219,353 |
| 2026-10-08 | Reed Joshua SVP, Chief Financial Officer | Option exercise | +9,164 | 9,164 | ||
| 2026-10-08 | Reed Joshua SVP, Chief Financial Officer | Shares withheld for taxes | −4,069 | $40.11 | $163K | 5,095 |
| 2026-10-08 | Reed Joshua SVP, Chief Financial Officer | Option exercise · Restricted Stock Unit Award | −9,164 | 27,492 | ||
| 2026-10-07 | Whitaker Anne Clem Director | Grant or award · Restricted Stock Unit Award | +7,239 | 7,239 | ||
| 2026-10-07 | Whitaker Anne Clem Director | Grant or award · Non Qualified Stock Option (Right to Buy) | +17,998 | 17,998 | ||
| 2026-10-02 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,034 | $41.03 | $83K | 221,388 |
| 2026-09-03 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Sale 10b5-1 | −2,034 | $48.01 | $98K | 223,422 |
| 2026-09-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $24.59 | $123K | 74,389 |
| 2026-09-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −9,000 | $46.99 | $423K | 65,389 |
| 2026-09-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 61,276 | ||
| 2026-08-17 | Nichols Christian Todd SVP, Chief Commercial Officer | Sale 10b5-1 | −6,912 | $49.19 | $340K | 102,857 |
| 2026-08-17 | Nichols Christian Todd SVP, Chief Commercial Officer | Sale 10b5-1 | −664 | $49.65 | $33K | 102,193 |
| 2026-08-05 | Jackson Blair Curtis President & CEO, Alkermes plc | Grant or award · Employee Stock Option (Right to Buy) | +93,229 | 93,229 | ||
| 2026-08-05 | Jackson Blair Curtis President & CEO, Alkermes plc | Grant or award · Employee Stock Option (Right to Buy) | +124,305 | 124,305 | ||
| 2026-08-03 | snyderman nancy lynn MD Director | Option exercise | +27,948 | $46.72 | $1.3M | 43,343 |
| 2026-08-03 | snyderman nancy lynn MD Director | Option exercise | +16,524 | $46.72 | $772K | 59,867 |
| 2026-08-03 | snyderman nancy lynn MD Director | Sale | −44,472 | $50.35 | $2.2M | 15,395 |
| 2026-08-03 | snyderman nancy lynn MD Director | Option exercise · Non Qualified Stock Option (Right to Buy) | −27,948 | 0 | ||
| 2026-08-03 | snyderman nancy lynn MD Director | Option exercise · Non Qualified Stock Option (Right to Buy) | −16,524 | 0 |
Page 1 of 41 · 804 trades